Nikkei reports startup funding: BionicM raises ¥710 million, Quadlytics raises ¥600 million

The Nikkei reported on domestic startup fundraising on Nov. 7, 2026, highlighting BionicM’s ¥710 million raise and Quadlytics’ ¥600 million raise. BionicM raised ¥710 million in the first closing of its Series B round, bringing its cumulative funding, including equity and grants, to ¥2.58 billion. Quadlytics raised ¥600 million through a third-party allotment of shares and convertible bonds, bringing its cumulative funding to ¥1.32 billion.

BionicM’s funding is tied to plans to build production capacity and marketing and sales capabilities in the United States for ASISTA, which it plans to launch there in 2027. Quadlytics plans to use its funding not only for heart rate variability analysis and development of a seizure-warning device, but also for clinical development, regulatory affairs and quality assurance, underscoring the breadth of work required to commercialize a medical device.

The two funding rounds differ in focus. BionicM is preparing production and sales ahead of a planned U.S. launch in 2027, while Quadlytics is advancing research and development in heart rate variability analysis and seizure-warning technology, along with regulatory and quality assurance capabilities. The former is focused on manufacturing and sales preparations for a product launch; the latter is focused on technical and regulatory preparations to commercialize a medical device under development. The companies’ business stages cannot be compared solely by the size of their funding rounds. BionicM says its ASISTA is designed to assist with knee flexion and extension, rather than serving only as a support device. The funding will go toward both production capacity and marketing and sales capabilities in the United States, indicating that the company is preparing product supply and market development alongside technology development. Progress in building the planned manufacturing capacity and sales infrastructure will be one measure of how effectively the funding translates into commercialization ahead of the 2027 U.S. launch. Quadlytics is developing a software medical device to detect signs of seizures by combining measurements of autonomic nervous system changes from a wearable electrocardiograph with machine learning. The funding will support not only its analysis technology but also clinical development, international expansion, regulatory affairs and quality assurance. Commercialization will depend not only on signal-processing performance but also on medical-device evaluation and regulatory compliance in each region. The goal of issuing a warning minutes before a seizure is the company’s stated aim and should be distinguished from demonstrated detection performance or clinical utility. The funding differs in purpose and business stage from the retail-robot deployments covered by this newspaper, such as MUSE begins deployment of its store robot “Armo” at Foodcellar Market in New York City and Simbe Robotics’ Tally reaches 3,000 units cumulatively. Those reports described deployments and unit counts in stores, while BionicM’s funding is for production and sales preparations before a U.S. launch, and Quadlytics’ is for medical-device development and commercialization preparations. They should not be treated as comparable deployment records. For devices that act on the body, manufacturing, clinical work and regulatory compliance are additional conditions for commercialization. Key developments to watch include the timing of ASISTA’s launch and its actual supply capacity, Quadlytics’ clinical and regulatory progress, and data supporting the seizure-warning device’s detection performance.

BionicM will use the funding to build production capacity for ASISTA, its next-generation powered prosthetic leg, which it plans to launch in the U.S. market in 2027, and to strengthen its marketing and sales capabilities there. The company says ASISTA has a “flexion and extension assist function” that helps bend and straighten the knee. The plan is to advance product development for U.S. sales alongside the development of its business infrastructure. Quadlytics will use the funding for research and development of heart rate variability (HRV) measurement and analysis technology, development and international expansion of seizure-warning technology, and stronger business infrastructure, including quality assurance and regulatory affairs. The seizure-warning device under development uses a wearable electrocardiograph to detect changes in the autonomic nervous system and combines that with machine-learning-based anomaly detection. The company says it aims to issue a warning minutes before a seizure.

BionicM is developing powered prosthetic legs based on research at the University of Tokyo and plans to build production capacity and local marketing and sales capabilities ahead of ASISTA’s U.S. launch. It is a concrete example of the manufacturing and sales preparations, in addition to technology development, required to bring robotics technology developed in Japan to the U.S. medical-device market.